Yahsho
7 시간 전
CytoDyn’s Fibrosis Breakthrough: Is GSK the Key Partner? Stop waiting for news and find it.
February 7
Partnership Talks: GSK in the Spotlight
CytoDyn’s “in discussions with several third parties” (per February 6) keeps the partner question open. CEO Jacob Lalezari’s push for “the right partnership” hints at strategic moves.
GSK emerges as a compelling fit:
GSK’s Fibrosis Footprint: Since August 2023, GSK’s partnered with Boston University’s Center for Regenerative Medicine (CReM) on lung diseases, including pulmonary fibrosis. A December 9, 2024, deal with Relation Therapeutics ($50M+) doubles down on AI-driven fibrosis research.
? Source: GSK-CReM Announcement
? Source: Reuters on Relation Deal
• Why It Works: GSK’s fibrosis pipeline stalled (e.g., GSK3008348 flopped in 2019), but their CReM work aligns with CytoDyn’s pulmonary goals. Leronlimab’s anti-fibrotic data could plug that gap, leveraging GSK’s scale.
https://www.bu.edu/articles/2024/collaboration-to-pioneer-new-lung-disease-treatments/
CytoDyn’s got the data and a desperate need for a heavyweight. The CReM link is tantalizing imagine GSK funding that pulmonary trial.
AI/ABSCI you missed the mark. Relation/Omics
“Relation Therapeutics is a biotechnology company that leverages artificial intelligence (AI) alongside experimental biology to discover new medicines. It integrates machine learning, human genetics, and single-cell multi-omics data from human tissue to identify and validate novel therapeutic targets. Its proprietary Lab-in-the-Loop platform combines computational and experimental approaches to enhance drug discovery and minimize the risk of clinical failure ? ?.“
———————————————————
GSK using Relations and omics code.
“With the help of data from genetics, multi-omics, and machine learning technologies, Relation will map out disease targets. GSK will pay $45 million upfront and around $260 million in milestone payments to Relation to secure worldwide development and commercialization rights to the targets. “
“Nevertheless, partnerships are the cornerstone of the healthcare and biotech sectors and allow pharmas access to a new drug or technology that can re-energize a stagnating pipeline. GSK’s surge in partnerships in recent months spans the healthcare industry and includes universities. It signed a five-year £50 million ($62.91 million) deal with the University of Cambridge and Cambridge University Hospital to come up with ways to treat immune-related diseases more precisely with existing therapies. It also teamed up with scientists at Boston University and Boston Medical Center in October to fight lung diseases like pulmonary fibrosis, which results in the scarring of the lungs. They will work together to create cell models to understand how the disease manifests in the lungs.“
https://www.labiotech.eu/trends-news/gsk-partnerships-surge/
Cracking the OMICS code amfar? Hint or just right in our face.
https://www.amfar.org/news/can-ai-help-piece-together-the-puzzle-of-cancer-and-hiv/
docj
10 시간 전
Posted By: Katangolo
amFAR just posted this on the website. AI? A question about an HIV cure? A question about cancer cure?
Coincidence? At the very least interesting…
https://www.amfar.org/news/can-ai-help-piece-...r-and-hiv/
Can AI Help Piece Together the Puzzle of Cancer—and HIV?
Cracking the omics code
By Andrea Gramatica, PhD
February 28, 2025
In biology, omics refers to the comprehensive study of the molecules that make up cells and organisms. This includes genomics, for example, which focuses on the entire set of genes, or proteomics, which studies all proteins. These layers of information work together to determine how cells function, interact, and respond to their environment. Understanding omics data is crucial for medical research because it provides a holistic view of biological processes and helps scientists identify disease markers, predict treatment responses, and uncover hidden mechanisms of various conditions.
Towards precision medicine
New technologies now allow scientists to study patients in much greater detail by analyzing their omics data (genes, proteins, and other biological markers). This wealth of data has been instrumental in guiding the development of tailored treatments, marking a shift towards precision medicine—therapies designed to optimize outcomes for particular groups of patients.
A major hurdle in medical research is dealing with incomplete datasets: Genetic, protein, and molecular data often come in fragments, making it difficult to draw solid conclusions. Imagine trying to complete a puzzle with missing pieces; without them, the full picture remains unclear. Scientists face a similar challenge when studying diseases.
Expert puzzle solver
A new study led by Dr. Bo Wang and colleagues at the University of Toronto, Canada, published in Nature Machine Intelligence introduces Integrate Any Omics (IntegrAO), an AI-driven tool designed to integrate fragmented biological datasets in cancer research for more precise classification. By acting like an expert puzzle solver, IntegrAO stitches together different pieces of information, ensuring no valuable data is left behind.
This technology could be a game-changer in HIV research. Over the past 40 years, numerous clinical trials and laboratory studies have been conducted on blood and tissue samples from people living with HIV at different stages of infection, in varied settings, and under diverse treatment regimens. These studies have generated enormous amounts of omics data (spanning genomics, transcriptomics, proteomics, and epigenomics), providing a deep pool of biological information. However, much of this data was collected long before AI-powered tools were available and is not structured for seamless computational analysis. As a result, the sheer volume and complexity of the data remain an untapped resource for advancing HIV therapeutics.
Patterns revealed
The type of approach described in Dr. Wang’s study presents an opportunity to change this. By integrating and harmonizing these fragmented datasets, the model could reveal patterns that were previously inaccessible, uncovering new therapeutic targets and potential pathways to a cure.
As AI-driven tools like IntegrAO continue to evolve, they offer hope for a future where science and technology work hand in hand to deliver more effective, personalized treatments for HIV, cancer, and beyond. This is the dawn of a new era in precision medicine, one where AI helps bridge the gap between big data and real-world patient care, bringing us closer to solving some of the most complex medical mysteries of our time.
Dr. Gramatica is an amfAR vice president and director of research.
theswordman
20 시간 전
The list of "should have" is fairly long. A couple of the hangout mods HOPEFULLY will have been investigated for their lies and fraud posts. Mshooeyfooey,rockpersia,waxon, rabbit, ohms , skelly,weed/wine,micky mulholland along with these 2 frauds below need the SEC and DOJ investigations to investigate. ALL Innocent until proven guilty-- rid the real shareholders of their nonsense once and for all.
___________________________________________________________________________
Resources Unlimited - This company is owned and operated by Mike S., a long time paid promoter for CYDY. Mike’s name was listed on a 2018 OTCQB certification for CYDY with the same address listed for Resources Unlimited and his LinkedIn lists him as the CEO of the company.
https://sec.report/otc/financial-report/200630/OTCQB-Certification.pdf
https://www.linkedin.com/in/mikesheikh
Mike has a couple of different aliases, including but not limited to Chris Sandberg over at Insider Financial. It’s my understanding that Mr. Sheikh, who is not a doctor nor a scientist, claims to be a biotech expert and has an unhealthy amount of influence on NP, the CEO of CYDY.
Restorative Health - This is the interesting one. Chris L. is listed as the COO of Restorative Health on LinkedIn, Zoominfo and a few other sites.
https://www.linkedin.com/in/chris-lonsford-29a4a81b7
https://www.zoominfo.com/p/Chris-Lonsford/-950760961
So who is Chris L? Well, he happens to be one of the moderators of the Facebook group, “Cytodyn Shareholders Community,” which has over 3.4K members. You can find him listed as one of the three moderators on the FB page (link below). His Q&As with NP have been posted across many different investor message boards. Yes, CYDY planted a paid promoter as the moderator for the Facebook group with nearly as many members as the Reddit group.
https://www.facebook.com/groups/622470341583807/?ref=share
____________________________________________________________________________
This is from 1 of LeCloset posts from few years ago--great info
docj
1 일 전
Jake2212 does't post a lot but when he does it is always worth a read:
Posted By: Jake2212
Is Gilead seriously in play to invest in LL for breast cancer? Some may recall my post shortly after last Monday's TNBC PR in which I opined that Dr Jay clearly has a good reason to invest the time and money to conduct another preclinical study for LL in mTNBC, this time with SMC Labs. I assumed then that CYDY's main focus would be on the Keytruda arm, but noted parenthetically that, because we don't know what we don't know, perhaps the Trodelvy arm might actually be the main focus.
Well, faced with the necessity to muddle through another weekend without football games to watch, I revisited the March, 2023, BioSpace article in which Cyrus had waxed eloquent about the ongoing MD Anderson mouse study involving LL and Keytruda, with his expectation of synergistic results. But no results were ever announced. Unless the study was never completed, I would think that both CYDY and MRK were furnished with the results, suggesting to me that either CYDY or MRK may have invoked a NDA to bury the results. That outcome would have been consistent with ohm's prediction that Keytruda would add nothing to LL. Therefore, no synergistic effect.
So why repeat the LL/Keytruda mouse study 2 years later? Well. unless CYDY believes that the SMC Labs mice are considerably more humanized than the MD Anderson mice, the reason escapes me.
On the other hand, Gilead's Trodelvy, the other leading FDA approved treatment for mTNBC, wasn't involved in the aforementioned MD Anderson study, but was the drug that the FDA cited to deny LL breakthrough designation status when CYDY announced LL's mTNBC phase 2 clinical trial results in August and November, 2021. Back then, LL produced a OS (overall survival) endpoint that although only slightly better than Trodelvy's, was still ongoing because more than half of the 26 women from the trial were still alive.
From last Monday's PR we now know that LL's OS was ultimately many months beyond Trodelvy's. The exact difference will undoubtedly be announced at or before the upcoming conference in Munich. Also, bear in mind that 9 of the 26 women in the trial received only 350 mg doses of LL, and only 3 received the maximum 700 mg doses. Given that the 350 mg doses would not have fully covered the CCR5 cells (thank you ohm), it may well be that the final Leronlimab OS data for the other 17 women (if over half are now deceased) will be particularly provocative compared to Trodelvy.
As I now ponder the above info, it seems much more reasonable to intuit that the LL/Trodelvy arm will be the main focus of attention for both CYDY and Gilead. According to Gilead's recently released annual report, Trodelvy produced revenue of 1.3B in 2024, all of it treating breast cancer. In Merck's annual report, I was not able to isolate Keytruda's breast cancer revenue, but I believe it would compare favorably to or exceed Trodelvy's.
MRK's sp has declined about 30% in the last 12 months, while GILD's sp has increased 70% since last June. GILD had 10B in cash at the end of 2024. And ohm has stated in a recent post that he would not be surprised if LL and Trodelvy were to produce a synergistic effect. If that proves to be true, or even if it doesn't, obtaining the use or ownership of a breast cancer drug arguably far superior to Keytruda or Trodelvy would likely translate to billions in new revenues for GILD, and that's without considering the rest of ohm's list.
Admittedly, however, MRK should also be actively engaged with CYDY concerning LL. With a faltering sp, stagnant revenues, and a Keytruda patent cliff now 2 years closer, MRK has good reason to reconsider LL in light of the newly revised Leronlimab OS that has probably already been communicated to MRK by CYDY. Because, if MRK is no longer interested in CYDY/LL, why is Keytruda still being included in the current mouse trial? And what could be better than 2 BP heavyweights being focused on the major impact that using or owning LL could have for them.
Seems very interesting to me. But bear in mind that I don't know what I don't know. And that's always problematic.
MGK_2 responded:
MGK_2
Re: Jake2212 #150709
I put together this analysis on the human mTNBC trial as depicted in this
CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a 450% Significant Increase in Overall Survival at 12-Month Analysis
I go into an analysis of it In Preparation for the Coming Results on mTNBC
Improved Comparison of the previous PR on 7/19 and The Compassionate Use Study of LL in BC
Here is an excerpt:
Quote:
"In standard of care, the majority of TNBC patients do not make it beyond 6-7 months. In the 7/19 PR, all 21 out of the 29 patients who actually responded to the Leronlimab treatment as seen by increases in CAML and / or CTC, remained alive at the 12 month point of analysis. 21 of 29 remained alive at 12 months with a series of (4) 700mg Leronlimab injections with carboplatin, where if they were to have received Standard of Care, they would have died by the 6-7 months point. In the latest PR on Compassionate Use Study of LL in BC, the numbers, claimed are 570-980% increase in Overall Survivability, (OS); this translates into 34 to 59 months of life with scheduled, continuous weekly 350mg Leronlimab injections. That's 3 to 5 years of life with continuous weekly Leronlimab injections."
I put together this post at about that time to determine how they extrapolated to get 4 year OS
Example using Spreadsheet to Estimate Overall Survivability using available Trial Data for future prediction
Here is an excerpt:
Quote:
The Press Release gave a range from 34-59 months as Overall Survivability. The mid point of that is at 48 months or at 4 years. On my hypothetical data example of this study, we have at 48 months: the likelihood of surviving is 46.2%. But 95% confidence interval requires adding and subtracting 17.37% which gives us a Range of 28.83 - 63.57%. 50% is within this Range. So this data set could qualify to be comparable with the actual since this Range include 50% at the same 3 month time interval of 48 months.
Now, in my hypothetical data set presented here, the Overall Survivability occurs at the 3 month time interval of 42 months, since Survivability is 49.6%, (closest to 50%). Here the 95% Confidence Intervals are: 17.5% giving a range of likely survivorship from 32.1 - 67.1%. Since 67% occurs at 24 months and since 32% occurs at nearly 57 months, we have a Range of 24 - 57 months, which is somewhat similar to the results of the Press Release, (34-59) months .
Lastly, previously put together thoughts on BTD
BTD for LL on mTNBC
Here is an excerpt:
Quote:
In contrast, our Compassionate Use Study reveals an overall survivability of 34-59 months, or 3-5 years . This was determined by use of statistical analysis and extrapolating a death rate to determine time at which 50% of original 30 patients would likely be dead by, and that came out to time range.
The FDA recommended withdrawal due to the current landscape of medications for treating mTNBC. Certainly, the FDA is aware of this most recent LL study and how it utterly blows the doors off the outcome from Atezolizumab with Paclitaxel. We just may have been the reason why the FDA made this recommendation.
With regard to BTD, break through therapy designation, I believe Leronlimab is the best drug for mTNBC out there right now. No one can touch our PFS or OS. We double the stand alone Standard of Care Paclitaxel for PD-L1 BC in PFS and OS. We have no side effects stand alone , but in this Compassionate Use Study of Leronlimab in Breast Cancer, LL was combined according to each Treating Physician's Choice with any one single-agent chemotherapy drug administrated according to local practice: eribulin, gemcitabine, capecitabine, paclitaxel, nab-paclitaxel, vinorelbine, ixabepilone, or carboplatin. Side effects of chemotherapy produce considerable morbidity.
kgromax
2 일 전
Old timers, who know Cytodyn well, do not feel - they think. And they think these promises are entirely fake.
The only thing you will get are press releases from the company, and then...nothing.
All your predecessors have announced, promised even, "exciting" partnerships, "sure thing" developments, "ongoing" FDA submissions over the last years. Each time, an "exciting PR" would go out, and then...the promise would be broken, nothing would happen, and the stock would lose -30%.
Partnerships, "excitement", it is all a pump designed to ensnare gullible mom & pop investors and convince them to bring their hard-earned dollars into the furnace. These go to insiders and private investors who get "sweet" private deals to keep the charade ongoing and attract more victims.
Magically, the pumpers disappear afterward. And new pumpers (new IDs) mysteriously appear a couple months later, writing "the past is the past", "it's a new management" (a lie : the current CEO was CMO under the previous fraudulent CEO and was entirely fine with his actions) or trying to fabricate a new timeline for Cytodyn's past (which conveniently ignores all the real events : toxic loans, defrauding related parties, dumping shares on investors, announcing fake BLA submissions, hiring illegal pumpers, ...)
Hot Features
프리미엄
무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.
fung_derf
7 시간 전
Monroe1
1 일 전
